Non–Small Cell Lung Cancer Coverage from Every Angle

Benjamin Besse, MD, PhD, on Clinical Tips for Prescribing Atezolizumab as Neoadjuvant Therapy for Resectable NSCLC

Posted: Sunday, October 4, 2020

Benjamin Besse, MD, PhD, of the Gustave Roussy Cancer Centre, talks about the neoadjuvant setting for atezolizumab in resectable non–small cell lung cancer, tips for clinicians prescribing this medication, and how to manage adverse effects of a drug that has shown some activity in early studies.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.